Community-acquired pneumonia (CAP) is a common illness that causes significant morbidity and mortality, particularly among elderly individuals and in those with serious comorbidities. Common etiologies of CAP, such as Streptococcus pneumoniae and Staphylococcus aureus, increasingly have become resistant to available treatment options due to the overuse of antibiotics and mutations encouraged by the pneumococcal vaccine. These evolving resistance profiles and vaccine replacement serotypes underscore the need to develop safe and effective agents for the treatment of CAP.
 
This Special Report discusses the epidemiology of CAP, an overview of current treatment issues, and the use of TEFLARO (ceftaroline fosamil), a third-generation cephalosporin for the treatment of CAP caused by designated susceptible bacteria.

Download to read this article in PDF document:
Teflaro® (ceftaroline fosamil) for the Treatment of Community-Acquired Bacterial Pneumonia Caused by Designated Susceptible Bacteria

This article is in PDF format and it requires Abobe Reader. If you do not have Adobe Reader installed on your computer then please download and install from the link below.